Welcome to our dedicated page for Estrella Immunopharma news (Ticker: ESLAW), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies for cancers and autoimmune diseases. The Estrella news feed highlights company announcements that trace the progress of its immunotherapy pipeline, capital markets activity, and corporate developments.
News items feature detailed updates on EB103, Estrella’s CD19-Redirected ARTEMIS T-cell therapy, including milestones from the ongoing STARLIGHT-1 Phase I/II clinical trial in relapsed or refractory B-cell non-Hodgkin lymphoma. Press releases have described early safety and efficacy observations, such as completion of the first dose cohort, Data and Safety Monitoring Board decisions to advance to higher dose levels, and a reported complete response in the first patient treated.
Investors and followers of immuno-oncology can also review coverage of financing transactions, such as a registered direct offering and concurrent private placement that generated approximately $8.0 million in gross proceeds, along with the stated intended use of funds for general corporate purposes and working capital. Additional news includes analyst coverage initiations, where D. Boral Capital LLC outlined its view of Estrella’s ARTEMIS platform and EB103 program, and corporate governance updates such as the appointment of Hong Zhang as Chairperson of the Board.
This page aggregates Estrella’s official communications so readers can follow clinical trial progress, pipeline developments, securities offerings, and board-level changes related to ESLA and ESLAW over time.
Estrella Immunopharma (NASDAQ: ESLA) received initiating coverage from Zacks Small-Cap Research on March 23, 2026, with a $12.00 per share valuation. Zacks highlighted the differentiated ARTEMIS T-cell platform and encouraging Phase I STARLIGHT-1 data for EB103, including a 100% CR at Month 1 in the high-dose cohort (5 evaluable patients) and no Grade 3+ CRS reported.
The report notes favorable safety signals, heavily pretreated/high-risk patient enrollment, CR durations of 3–18 months to date, and that the valuation reflects Zacks SCR’s independent probability-adjusted DCF analysis.
Estrella Immunopharma (Nasdaq: ESLA) presented updated STARLIGHT-1 Phase I data showing promising clinical activity for EB103, a CD19-redirected ARTEMIS T-cell therapy, in aggressive B-cell non-Hodgkin lymphoma.
Key highlights: 100% complete response (CR) in the high-dose cohort at Month 1 (all CRs remain through data cutoff), response durations of 3–18 months with median DOCR not yet reached, one complete responder with PCNSL, and no treatment-related serious adverse events reported in the nine-patient cohort.
Estrella Immunopharma (NASDAQ: ESLA) closed a registered direct offering and a concurrent private placement on January 6, 2026, raising approximately $8.0 million aggregate gross proceeds.
The company issued 4,063,290 common shares and 1,000,000 pre-funded warrants; it also issued common warrants to purchase up to 7,594,935 shares. The combined price per share with warrant was $1.58 (pre-funded $1.57999). Pre-funded warrants carry a $0.00001 exercise price and no expiration; common warrants have a $1.39 strike and five-year term. Net proceeds are planned for general corporate purposes and to advance the lead program, EB103, through Phase II.
Estrella Immunopharma (NASDAQ: ESLA) has successfully completed the first dose cohort in its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-Redirected ARTEMIS® T-cell therapy. The Data and Safety Monitoring Board has approved advancing to the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight.
The trial, targeting patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who failed multiple prior therapies, showed promising preliminary results. The first cohort demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events. Notably, tumor response was observed in all patients at Month 1.
The STARLIGHT-1 trial follows a standard 3+3 dose-escalation design, aiming to evaluate safety, tolerability, and preliminary efficacy of EB103 in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA) received a Buy rating with a $16.00 price target from D. Boral Capital. The analysis focuses on EB103's development in B-cell Non-Hodgkin's Lymphoma and the company's ARTEMIS® T-cell engineering platform, which mimics natural T-cell receptor mechanisms for a more regulated immune response.
The valuation model incorporates a 30% probability of success and a 30% discount rate, reflecting the early clinical development stage. EB103 is currently in Phase I/II trials for relapsed/refractory and high-risk blood cancers. The company has an engagement agreement with D. Boral Capital for investment banking services, including potential underwriting and placement agent roles.
Estrella Immunopharma (NASDAQ: ESLA) has reported a complete response in the first patient treated with EB103 CD19-Redirected ARTEMIS® T-cells in its STARLIGHT-1 Phase I/II clinical trial. The patient, diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms, achieved this response one month after treatment. Notably, no treatment-related serious adverse events were observed, despite the patient's high-risk profile.
Dr. Cheng Liu, CEO of Estrella, expressed cautious optimism about these early results, highlighting the company's goal to develop T-cell therapies that match or exceed the efficacy of current CAR-T therapies while improving safety. The STARLIGHT-1 trial aims to assess EB103's safety and determine the Recommended Phase II Dose in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA, ESLAW) has appointed Hong Zhang as Chairperson and Board member, expanding the board from five to six directors. This follows the company's recent milestone of dosing the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. Ms. Zhang brings over 25 years of financial and corporate strategy experience, having held key positions at Incinta Medical Group, Beijing Ocean Co-stone Capital Investment Management, and UOB Investment (China). CEO Dr. Cheng Liu, who previously served as Chairman, will continue as a board director.